Screener
Xenon Pharmaceuticals XENE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's cash & equivalents?
- Xenon Pharmaceuticals (XENE) reported cash & equivalents of $119.53M in Q2 2026.
- How has Xenon Pharmaceuticals's cash & equivalents changed year-over-year?
- Xenon Pharmaceuticals's cash & equivalents decreased by 11.7% year-over-year, from $135.38M to $119.53M.
- What is the long-term trend for Xenon Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's cash & equivalents has grown at a 34.6% compound annual growth rate (CAGR), from $45.01M to $199.16M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Xenon Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude